Paul Tudor Jones Eliem Therapeutics, Inc. Transaction History

Tudor Investment Corp Et Al

$15.5 Billion
Q1 2024

A detailed history of Paul Tudor Jones (Tudor Investment Corp Et Al) transactions in Eliem Therapeutics, Inc. stock. As of the latest transaction made, Tudor Investment Corp Et Al holds 29,466 shares of ELYM stock, worth $227,182. This represents 0.0% of its overall portfolio holdings.

Number of Shares

29,466

Previous 29,490 0.08%

Holding current value

$227,182

Previous $79,000 1.27%

% of portfolio

0.0%

Previous 0.0%

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$2.54 - $2.98 $60 - $71	-24 Reduced 0.08%	29,466 $80,000
Q4 2023 Feb 14, 2024	SELL	$2.45 - $2.85 $524 - $609	-214 Reduced 0.72%	29,490 $79,000
Q3 2023 Nov 15, 2023	SELL	$2.48 - $3.15 $4 - $6	-2 Reduced 0.01%	29,704 $78,000
Q1 2023 May 15, 2023	SELL	$2.3 - $4.64 $2,072 - $4,180	-901 Reduced 2.94%	29,706 $86,000
Q4 2022 Feb 14, 2023	SELL	$2.48 - $3.67 $29 - $44	-12 Reduced 0.04%	30,607 $112,000

Q2 2022 Aug 15, 2022	SELL	$2.77 - $8.4 $42,860 - $129,973	-15,473 Reduced 33.57%	30,619 $92,000
Q1 2022 May 16, 2022	SELL	$8.01 - $13.15 $1.2 Million - $1.96 Million	-149,366 Reduced 76.42%	46,092 $387,000
Q4 2021 Feb 14, 2022	SELL	$8.61 - $20.47 $790,707 - $1.88 Million	-91,836 Reduced 31.97%	195,458 $2.04 Million
Q3 2021 Nov 15, 2021	BUY	$14.45 - $28.61 $4.15 Million - $8.22 Million	287,294 New	287,294 $5.17 Million

Others Institutions Holding ELYM

# of Institutions

Shares Held

3.7M

Call Options Held

Put Options Held

View Full List

About Eliem Therapeutics, Inc.

Ticker ELYM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 26,567,700
Market Cap $205M
Description
Eliem Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in chronic pain, neuropsychiatry, epilepsy, and other disorders of the peripheral and central nervous systems. Its two lead drug candidates are ETX-810 for chronic pain, which is in Phase II...

More about ELYM

Track Paul Tudor Jones's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Tudor Investment Corp Et Al, based on Form 13F filings with the SEC.

News

Stay updated on Tudor Investment Corp Et Al and Paul Tudor Jones with notifications on news.

Account